Protein vaccines articles from across Nature Portfolio

The authors report that maternal RSV vaccination induces robust affinity-matured neutralizing antibodies in mothers and infants. Antibody transfer increased after 36 weeks, supporting current vaccination recommendations, and suggesting that early vaccination may benefit preterm-risk pregnancies.

A vaccination strategy using heterologous HIV Env trimers covalently coupled to liposomes for multivalent display generates cross-neutralizing HIV serum antibody responses in non-human primates, mimicking infection-elicited apex-targeting broadly neutralizing antibodies.

Authors evaluate and present the safety and immunogenicity results of an influenza vaccine, showing protection against H5N1 challenge. The study demonstrates proof-of-concept, highlighting the potential for a key component of a future universal flu vaccine.

Mucosal administration of a multivalent, adjuvanted vaccine against Clostridioides difficile promoted bacterial clearance and protected against morbidity, mortality, tissue damage and recurrence in mice.

CD25 modulation with SARS-CoV-2 subunit vaccine enhances broadly neutralizing antibody responses by rapidly inhibiting Treg cells and promoting early germinal center reactions.

Hepatitis C virus remains a health burden due to the lack of an effective vaccine, hindered by difficulties in replicating the native E1E2 antigen structure. Here, the authors engineer a stabilized E1E2 heterodimer using cryo-EM-guided modifications, enhancing immunogenicity and paving the way for future HCV vaccine development.

The identification of a new Asn332 glycan-independent anti-HIV-1 neutralizing antibody that targets the V3 epitope, together with an Asn332 glycan-deficient priming immunogen capable of inducing B cell precursors of Asn332 glycan-dependent and -independent neutralizing antibodies, redefines the V3 loop in HIV-1 vaccine development.

An engineered nanobody enables modular display of multiple viral epitopes onto a single protein-based nanoparticle, leading to broad-spectrum immunization.

In this proof-of-concept study, we present a next-generation poxvirus vaccine that features a ‘two-in-one’ immunogen. Our protein vaccine construct, DAM, combines the monkeypox virus antigens A35 and M1, and was produced on the basis of structure-guided design. The DAM subunit vaccine elicited superior antiviral immunity with safety compared to cocktail vaccines or a live vaccinia virus vaccine.